Zacks Investment Research Downgrades AEterna Zentaris (NASDAQ:AEZS) to Hold

Zacks Investment Research cut shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a buy rating to a hold rating in a research note issued to investors on Monday morning, reports.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Other equities analysts have also issued reports about the stock. ValuEngine raised shares of AEterna Zentaris from a hold rating to a buy rating in a report on Thursday, October 31st. HC Wainwright reissued a buy rating on shares of AEterna Zentaris in a research note on Thursday, August 15th. Four investment analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus price target of $2.00.

Shares of NASDAQ:AEZS traded up $0.03 during trading on Monday, hitting $1.05. 197,600 shares of the stock traded hands, compared to its average volume of 209,808. The company has a market cap of $20.84 million, a price-to-earnings ratio of 4.20 and a beta of 1.11. The company has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $2.28. AEterna Zentaris has a 52-week low of $0.81 and a 52-week high of $5.57.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.15. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.20 million. AEterna Zentaris had a negative net margin of 536.79% and a negative return on equity of 1,428.66%. As a group, equities research analysts anticipate that AEterna Zentaris will post 1.77 EPS for the current fiscal year.

An institutional investor recently bought a new position in AEterna Zentaris stock. Creative Planning purchased a new stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $30,000. Creative Planning owned 0.06% of AEterna Zentaris as of its most recent filing with the SEC. 7.03% of the stock is owned by hedge funds and other institutional investors.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.